Azithromycin: 5 agencies, 2011–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 14.7 years separate the first record, 2 Nov 2011 at AWMSG (Wales), from the most recent, 2026 at PBAC (Australia).
AWMSG (Wales) changed its position: not recommended on 2 Nov 2011, restricted by 14 Aug 2014, after a resubmission.
No assessment is on file from HAS (France), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for azithromycin, 1 submission was never made — an outcome set by the company rather than the assessor.
6 distinct indication wordings are recorded for azithromycin by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 13 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess azithromycin, on 2 Nov 2011; PBAC (Australia) did not open a file until 2026 — an unusually long tail of 14.7 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 6 years in total.
3 of the 5 agencies here assessed azithromycin more than once, PHARMAC (New Zealand) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed azithromycin.
The full ledger for azithromycin reads 6 recommended, 2 other, 2 not recommended and 1 restricted, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 20 May 2026 | Indicación terapéutica autorizada: Azitromicina Altan 500 mg polvo para solución está indicado para el tratamiento de la… | financed by the SNS · art. 92 a, d | source |
| PHARMAC (New Zealand) | 13 Oct 2016 | Pertussis | PTAC advice: No Formal Recommendation · decision reached | source |
| PHARMAC (New Zealand) | 13 Oct 2016 | Bronchiectasis - non-cystic fibrosis, in children with high exacerbation or hospitalisation rates | PTAC advice: Recommended alteration to access criteria · decision reached | source |
| AWMSG (Wales) | 14 Aug 2014 | Treatment of community-acquired pneumonia due to susceptible microorganisms in adult patients where initial intravenous … | recommended with restrictions (limited) | source |
| SMC (Scotland) | 9 Jul 2012 | Local antibacterial treatment of conjunctivitis caused by susceptible strains: - Purulent bacterial conjunctivitis, Trachomatous conjunctivitis caused by Chlamydia tracho… | not recommended | source |
8 further decisions for azithromycin, across 4 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- vutrisiran — also decided by CIPM in 2026Q2
- omalizumab — also decided by CIPM in 2026Q2
- finerenone — also decided by CIPM in 2026Q2
- ibrutinib — also decided by CIPM in 2026Q2
- patiromer — also decided by CIPM in 2026Q2
- ipilimumab — also decided by CIPM in 2026Q2
Coverage: 13 decisions for azithromycin from 5 agencies, 2011 to 2026. Data to 7 Sep 2026. ATC class J01F — Antibacterials. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.